Posted on July 5th, 2012 by
Mayo Clinic announced Tuesday that it has signed an agreement with Maryland-based A&G Pharmaceuticals that will ultimately pave the way for Mayo to offer the first commercial blood test to predict progranulin mutation status in patients suspected to havefrontotemporal dementia (FTD). Terms of the agreement were not disclosed.
MedCity News by Arundhati Parmar
You must be logged-in to the site to post a comment.